Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure

NCT ID: NCT02847312

Last Updated: 2016-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this proposed human trial, the investigators aim to establish whether 4 weeks of daily consumption of beta-glucan matched meals providing either a high dose or a moderate dose of oat avenanthramides and phenolic acids leads to dose-dependent chronic improvements in markers of CVD risk and gut health relative to an energy matched control intervention in healthy adults with above average blood pressure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* To investigate the chronic effects of daily intake of oat products on flow mediated dilatation of the brachial artery (FMD; primary endpoint), microvascular endothelial function (measured by laser Doppler iontophoresis), pulse wave analysis, gut microbiota diversity, 24h blood pressure, activity of the renin angiotensin system, markers related to cellular production of nitric oxide and reactive oxygen species, inflammatory cytokines, and further potentially emerging biochemical markers of CVD risk.
* To establish if phenolic acids and avenanthramides from oat products exert cardiovascular and microbial effects in a dose dependent manner.
* To measure urinary and fecal excretion of avenanthramide and phenolic acid metabolites.

To explore correlations between bacterial population changes and CVD risk markers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High avenanthramide, phenolic acid

66.8g Pepsico Oatmeal + 60g Oat cake

Group Type ACTIVE_COMPARATOR

High avenanthramide, phenolic acid

Intervention Type OTHER

High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.

Low avenanthramide, medium phenolic acid

17g Oatwell + 63.6g Cream of Rice + 60g Melba Toast

Group Type ACTIVE_COMPARATOR

Low avenanthramide, medium phenolic acid

Intervention Type OTHER

Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.

Control

69.8g Cream of Rice + 8.1g Cellulose + 4.8g Pectin + 60g Melba Toast

Group Type PLACEBO_COMPARATOR

Control

Intervention Type OTHER

Control are matched with energy and insoluable fibre.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High avenanthramide, phenolic acid

High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.

Intervention Type OTHER

Low avenanthramide, medium phenolic acid

Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.

Intervention Type OTHER

Control

Control are matched with energy and insoluable fibre.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Above average blood pressure (i.e. systolic 120-159 mmHg and diastolic 75-99 mmHg)

Exclusion Criteria

* Abnormal biochemical, haematological results as assessed at health screening
* Hypertension (i.e. SBP/DBP ≥160/100 mm Hg)
* BMI \>35
* Current smoker or ex-smoker ceasing \<3 months ago
* Past or existing medical history of vascular disease, diabetes, hepatic, renal, haematological, neurological, thyroidal disease or cancer
* Prescribed or taking lipid lowering, antihypertensive, vasoactive (e.g. Viagra), anti-inflammatory, antibiotic or antidepressant medication
* Allergies to whole grains
* Parallel participation in another research project
* Having flu vaccination or antibiotics within 3 months of trial start
* Chronic constipation, diarrhea or other chronic gastrointestinal complaint
* On a weight reduction regime or taking food, probiotics or prebiotics supplements or laxative within 3 months of trial start
* Performing high level of physical activity (i.e. ≥150min aerobic exercise/week)
* Consumption of ≥21 units of alcohol/week
* Females who are breast-feeding, may be pregnant, lactating or, if of reproductive age and not using a reliable form of contraception (including abstinence)
Minimum Eligible Age

25 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PepsiCo, Inc.

INDUSTRY

Sponsor Role collaborator

Rothamsted Research

UNKNOWN

Sponsor Role collaborator

Biotechnology and Biological Sciences Research Council

OTHER

Sponsor Role collaborator

University of Reading

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jeremy Paul Edward Spencer

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeremy P Spencer, Professor

Role: PRINCIPAL_INVESTIGATOR

University of Reading

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hugh Sinclair Unit of Human Nutrition

Reading, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jeremy P Spencer, Professor

Role: CONTACT

+44 (0) 118 378 8724 ext. 8724

Manuel Y Schar, PDRA

Role: CONTACT

+44 (0) 1183786394

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michelle Weech, Mananger

Role: primary

01183787771

Angelika Kristek, Assistant

Role: backup

0118378771

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Prograin3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oat Breakfast Satiety Study
NCT01372683 COMPLETED PHASE4
Effect of Oats on Lipid Profile
NCT02376660 COMPLETED NA